

24 Jul 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen's growth challenges; Novartis's view on large M&A; pharma's Q2 outlook; and MSD on Lagevrio.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 July 2022, including: [Novo Nordisk A/S](#) obesity drugs in US cost-effectiveness spotlight; [Biogen, Inc.](#)'s growth challenges; [Novartis AG](#)'s view on large M&A; pharma's Q2 outlook; and [MSD](#) on Lagevrio.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Novo Nordisk's Obesity Drugs Exceed ICER's Cost Effectiveness Thresholds](#)" - Scrip, 18 Jul, 2022.)

(Also see "[Without An Alzheimer's Blockbuster, Biogen Is A Ship Without A Growth Rudder](#)" - Scrip, 20 Jul, 2022.)

(Also see "[Novartis Finance Chief Rules Out Large M&A](#)" - Scrip, 19 Jul, 2022.)

(Also see "[Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop](#)" - Scrip, 15 Jul, 2022.)

(Also see "[MSD's Asia Pacific Chief On Lagevrio's Gains In Clinical Utility Amid Paxlovid Luster](#)" -

Scrip, 19 Jul, 2022.)

[Click here to explore this interactive content online](#) ✎